Clinical trials: QT Prolongation
Long QT Syndrome, Wide QRS Complexes
ECG Signal Collection From Long QT Syndrome, Wide QRS Complexes, Heart Failure, and Cardiac Resynchronization Patients
The purpose of this study is to collect surface electrograms from standard and several non-standard configurations in patients with long QT syndrome, heart failure, cardiac resynchronization therapy or wide QRS during a routine…
- Conditions
- Long QT Syndrome, Wide QRS Complexes, Heart Failure, Cardiac Resynchronisation
- Trial name
- NCT00399412
- Testing
- subcutaneous ICD
- Where
- United Kingdom
- Volunteers
- 86 people
- Sponsor
- Boston Scientific Corporation
ECG, Pharmacokinetics
Evaluating QTc, PK, Safety of Gemtuzumab Ozogamicin (GO) in Patients With CD33+ R/R AML
This is a single-arm, open-label, Phase 4 study evaluating the effect of GO on the QTc, pharmacokinetics, safety, and immunogenicity of GO as a single-agent monotherapy in adult and pediatric patients with relapsed or refractory…
- Conditions
- ECG, Pharmacokinetics, Safety
- Trial name
- NCT03727750
- Testing
- Gemtuzumab Ozogamicin
- Where
- 24 sites in United States, Canada and 4 more
- Volunteers
- 51 people
- Sponsor
- Pfizer
Healthy Volunteers
A Pharmacokinetic And QT Study Of CP-751,871 In Healthy Subjects
This study is primarily to evaluate the single dose pharmacokinetics of CP-751,871 and its effect on QT interval prolongation.
- Trial name
- NCT00926263
- Testing
- CP-751,871, CP-751,871, moxifloxacin, saline
- Where
- United States
- Volunteers
- 28 people, healthy volunteers welcome
- Sponsor
- Pfizer
Long QT Syndrome Type 3
Effect of Eleclazine on Shortening of the QT Interval, Safety, and Tolerability in Adults With Long QT Syndrome Type 3
The primary objective of this study is to evaluate the effect of oral eleclazine on mean daytime QTcF interval after 24 weeks of treatment with elecalzine in participants with long QT syndrome Type 3.
- Trial name
- NCT02300558
- Testing
- Eleclazine
- Where
- 12 sites in United States, Canada and 6 more
- Volunteers
- 41 people
- Sponsor
- Gilead Sciences
Healthy
A Phase I Study of the Effects of APF530 Exposure, Granisetron and Moxifloxacin
This Phase I study will be performed in a double-blind, randomized, crossover design in healthy male and female subjects. The central ECG laboratory will be blinded to treatment.
- Trial name
- NCT01416259
- Testing
- Withdraw treatment
- Where
- United States
- Volunteers
- 56 people, healthy volunteers welcome
- Sponsor
- Heron Therapeutics
Healthy, Long QT Syndrome
Study Evaluating the Effects of Multiple Oral Doses of ERB-041 on Cardiac Repolarization in Healthy Subjects
To assess the effect of ERB-041 after multiple oral doses on cardiac repolarization as assessed by the QTc interval.
- Trial name
- NCT00316459
- Testing
- ERB-041
- Where
- United States
- Volunteers
- 64 people, healthy volunteers welcome
- Sponsor
- Wyeth is now a wholly owned subsidiary of Pfizer
Long QT Syndrome
Pharmacokinetics of Eleclazine in Adults With Normal and Impaired Hepatic Function
The primary objective of this study is to evaluate the pharmacokinetic (PK) profile of oral eleclazine and its metabolite, GS-623134, in participants with normal and impaired hepatic function.
- Trial name
- NCT02412098
- Testing
- Eleclazine
- Where
- 7 sites in United States, Germany and 2 more
- Volunteers
- 49 people, healthy volunteers welcome
- Sponsor
- Gilead Sciences
Long QT Syndrome Type 3, Long QT Syndrome 2
Observational Study to Describe Health-Related Quality of Life and Measure Disease Burden Among Patients With Long QT Syndrome Types (LQTS) 2 and 3
This is a cross-sectional observational study designed to assess the disease burden and quality of life in individuals with LQTS 2 and 3.
- Trial name
- NCT07075445
- Where
- United States
- Volunteers
- 200 people
- Sponsor
- Thryv Therapeutics, Inc.
Solid Tumors
A Study to Investigate the Effect of Single Dose of AZD6094 (600 mg) on Cardiac Repolarization in Healthy Volunteers
This is a randomized, placebo-controlled, double-blind, 3-way crossover phase I study being conducted on healthy volunteers to investigate the effect of single dose of AZD6094 (600 mg) on cardiac repolarization under…
- Trial name
- NCT03258515
- Testing
- AZD6094 200 mg, Moxifloxacin
- Where
- United States
- Volunteers
- 45 people, healthy volunteers welcome
- Sponsor
- AstraZeneca